Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Arguments for and against drug prohibition an emergency department visit does not mean that the drug was the cause of the visit. A document published for the non-profit advocacy organization Europe Against Drugs (EURAD) argues that "one cannot vote for a medicine" and that a scientific approval basis is essential. It says that EU rules set out strict criteria for the acceptance of a drug for medical use: According to Janet D. Lapey, M.D., of Concerned Citizens For Drug Prevention, " Due to a placebo effect, a patient may erroneously believe a drug is helpful when it is not. This is especially true of addictive, mind-altering